The booming demand for GLP-1 weight-loss drugs has created an opening for counterfeit and unapproved products from overseas. Even more concerning are questions about Chinese suppliers and whether companies connected to fentanyl precursor markets are also involved in the peptide supply chain.
That is why Tennessee Attorney General Jonathan Skrmetti and 19 other attorneys general are right to demand answers about foreign pharmaceutical ingredients entering the United States. If questionable suppliers can exploit regulatory loopholes to move unapproved ingredients into our country, Americans deserve to know what is entering our drug supply and who is manufacturing it.
This is about more than weight-loss drugs. It is about public health, supply-chain security and ensuring foreign bad actors cannot take advantage of gaps in American oversight.
Federal regulators should take these concerns seriously, tighten scrutiny of foreign suppliers and make sure unapproved GLP-1 ingredients are not slipping through the cracks.
Tennesseans should be able to trust that the medications they use are legitimate, properly manufactured, and safe. And, also FDA approved versions in consultation with a health care provider. Unfortunately, too many non-FDA approved versions are coming in across our border and being advertised to Tennesseans, including teenagers in deceptive and misleading ways. Attorney General Skrmetti and Senator Marsha Blackburn are asking important questions. Washington needs to provide answers.
– – –
Walter Blanks Jr. serves as the executive director of The Legacy Society.
